iFR-guided Revascularization in STEMI (WAVE)
iFR-guided Revascularization of Non-culprit Lesion in Patients With ST-segment Elevation Myocardial Infarction and Multivessel Disease (WAVE Registry): Long-term Outcome.
研究概览
地位
条件
详细说明
Background - Approximately 40-50% of patients undergoing primary PCI for STEMI have an occasional finding of multivessel coronary artery disease on angiography. In this setting there is a general consensus in the treatment of the culprit lesion (infarct related artery - IRA), while the literature provides contrasting evidence on the preventive treatment of non-culprit coronary lesions (not IRA). Four major randomized trials have, in fact, compared a complete revascularization strategy versus culprit-only revascularization during primary PCI: PRAMI trial, CULPRIT trial, DANAMI-3-PRIMULTI trial and Compare-Acute trial. Although all of these studies demonstrated a benefit in the composite cardiovascular end point in patients undergoing complete revascularization, no statistically significant difference in mortality was found. Therefore, at present, there is no definite evidence on the efficacy of non culprit lesion treatment on mortality and re-MI in patients with STEMI.
The recent guidelines of the European Society of Cardiology 2017 suggest however to evaluate the complete revascularization in multivessel patients before discharge (class IIa, level A). Previous randomized trials such as Compare-Acute study and DANAMI-3-Primulti showed that a complete revascularization strategy guided by FFR, during primary PCI, is associated with a significantly lower risk of cardiovascular events in patients with multivessel disease.
Furthermore, other studies demonstrated that an iFR-guided coronary revascularization is not inferior to FFR-guided revascularization in patients with stable coronary artery disease, whereas, it significantly reduces the overall duration of the procedure. The WAVE study recently demonstrated the diagnostic accuracy of iFR in functional assessment of non-culprit lesions in multivessel patients with STEMI, also highlighting the intralesional reproducibility of both FFR and iFR between baseline and staged. To date, however, there are no studies in the literature that have verified the long-term clinical impact of an iFR-guided revascularization during primary PCI for STEMI patients with multivessel coronary artery disease.
Aim of the study - Multicenter, observational registry to evaluate the long-term clinical impact of an iFR assessment of the non-culprit lesions during primary PCI for STEMI patients with multivessel coronary artery disease.
Methods - patients undergoing primary PCI for STEMI and presenting multivessel disease (at least another coronary stenosis ≥ 50% in addition to the culprit one on QCA analysis) will be enrolled. At the end of the revascularization procedure of the culprit lesion, the functional assessment of the non-culprit lesion will be performed through the use of iFR. In the case of iFR ≤ 0.89, the functionally critical lesion treatment will be performed during the same PCI procedure or staged (at the discretion of the operator and the center). On the other hand, patients with iFR> 0.89 will instead be directed towards a conservative approach with the implementation of clinical-instrumental follow-up.
A clinical follow-up will be performed in all patients by telephone interviews or outpatient visits at 12, 24 and 36 months from the index procedure.
The primary endpoint of the study is represented by the occurrence of Target Lesion Failure (TLF), a composite of cardiovascular death, non-fatal myocardial infarction, and ischemia-driven revascularization of the vessel previously assessed with iFR.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Carmine Musto, PhD, MD
- 电话号码:+393396361601
- 邮箱:cmusto@hotmail.it
学习地点
-
-
-
Roma、意大利、00152
- 招聘中
- Ospedale San Camillo
-
接触:
- Carmine Musto, PhD, MD
- 电话号码:+393396361601
- 邮箱:cmusto@hotmail.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- age> 18 years
- 12-hour chest pain with ST segment elevation greater than 0.1 mV in at least two contiguous leads treated with primary PCI
- presence of at least one non-culprit lesion with ≥50% stenosis in an epicardial vessel ≥2.5 mm
- informed consent signed
Exclusion Criteria:
- ejection fraction ≤ 30%
- presence of moderate / severe valvulopathies
- electrical instability and hemodynamics at the end of the index procedure (Killip III-IV class)
- TIMI flow <3 at the end of the index procedure
- previous myocardial infarction in the same territory of the non-culprit lesion
- previous coronary artery bypass grafting on the vessel undergoing functional assessment by iFR
- Inability to provide informed consent to the study
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Target Lesion Failure (TLF)
大体时间:12 months
|
A composite of cardiovascular death, non-fatal myocardial infarction, and ischemia-driven revascularization of the vessel previously assessed with iFR
|
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.